Crossmark

Survival impact of pathologic features after salvage lung resection following definitive chemoradiotherapy or systemic therapy for initially unresectable lung cancer

Crossref DOI link: https://doi.org/10.1007/s11748-024-02086-y

Published Online: 2024-09-27

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oka, Naoyuki

Hishida, Tomoyuki https://orcid.org/0000-0003-3417-8563
Kaseda, Kaoru

Suzuki, Yuri

Okubo, Yu

Masai, Kyohei

Asakura, Keisuke

Emoto, Katsura

Asamura, Hisao
License Information

Text and Data Mining valid from 2024-09-27

Version of Record valid from 2024-09-27
More Information

Article History

Received: 10 June 2024

Accepted: 18 September 2024

First Online: 27 September 2024

Declarations

:

: Naoyuki Oka, Tomoyuki Hishida, Kaoru Kaseda, Yu Okubo, Kyohei Masai, Keisuke Asakura, and Hisao Asamura have received research grants to their institution from Covidien Japan CO., LTD., Johnson & Johnson K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., and Eli Lilly Japan K.K. All other authors declare that there are no conflicts of interest. We certify that this submission is our original work and is not under review by any other publication.

Document is current

Any future updates will be listed below